Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials
- Siegel, David S
- Weisel, Katja C
- Dimopoulos, Meletios A
- Baz, Rachid
- Richardson, Paul
- Delforge, Michel
- Song, Kevin W
- San Miguel, Jesus F
- Moreau, Philippe
- Goldschmidt, Hartmut
- Jagannath, Sundar
- Yu, Xin
- Hong, Kevin
- Sternas, Lars
- Zaki, Mohamed
- Palumbo, Antonio
- CAVO, MICHELE
DOIAbstract
Renal impairment (RI) is a major comorbidity in patients with multiple myeloma (MM). Here we present the pooled safety and efficacy analysis of three clinical trials (MM-002, MM-003, and MM-010) of pomalidomide + low-dose dexamethasone (POM + LoDEX) in patients with moderate RI (creatinine clearance [CrCl] ≥ 30 to <60 mL/min) and without RI (≥ 60 mL/min). Trial protocols were approved by the institutional review board of each site involved. Patients with RI were older than patients without RI, although other baseline characteristics were similar. The dosing and safety profile of POM + LoDEX was similar across RI subgroups. Median overall response rate, progression-free survival, time to progression, and duration of response were not signifi...
Add to ORKG